gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · XFORHealthcareBiotechnology

X4 Pharmaceuticals, Inc. Common Stock (XFOR)

$3.24+2.21%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.24▼ 18.39% in range
Nov 4, 2025Low $2.45 · High $4.67Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

X4 Pharmaceuticals closed at $3.24 on Nov 4, up 2.21%, 30.6% below its 52-week closing high. Volume of 536.9K shares was 0.81× its 20-day average (close to normal).

Split-adjusted performance: +17.0% over one month, -26.0% over six months, -20.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $8.81M, up 346.3% from a year earlier, with a net margin of -183.5%.

Short interest was 7.5M shares at the Oct 15 settlement, down 1.3% from the prior report (9.3% of float, 12.5 days to cover).

Market cap$321.2M99.1M shares
Revenue · quarter$8.8M+346.3% YoY
Diluted EPS$-0.13—
P/E · TTM—P/S 20.3×
Net margin-183.5%Gross 81.6%
Dividend yieldNone
52-week range2.45 – 4.67−30.6% from high
Volume536.9K0.81× 20-day avg
Volatility · 60d60.9%Annualised
Short % of float9.3%12.5 days to cover
Net cash$131.2MCash $208.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.3%1M +17.0%3M −22.3%6M −26.0%YTD −19.0%1Y −20.8%3Y −85.3%5Y −97.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum45
Revenue growth90
Net margin55
Value (low P/E)—
Size57

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short7.5M−1.3% vs prior
Days to cover12.5Settled Oct 15
% of float9.3%
Short vol. 10d54.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
XFORX4 Pharmaceuticals$3.24+2.21%−26.0%+346.3%−183.5%—$321.2M
KYTXKyverna Therapeutics$5.160.00%−45.5%———$319.1MCompare
SCTXScribe Therapeutics$16.78+3.58%————$317.7MCompare
AGENAgenus$6.97+4.50%+79.2%+34.4%−1.7%3.4$314.8MCompare
IPSCCentury Therapeutics$1.67+9.87%−28.6%———$302.4MCompare
EIKNEikon Therapeutics$6.39+15.14%−35.9%———$346.1MCompare
OCGNOcugen$0.8745+17.35%−39.9%+8.4%−1671.8%—$296.6MCompare
SABSSAB Biotherapeutics$3.18+1.92%−16.3%———$289.3MCompare
FENCFennec Pharmaceuticals$10.35−3.27%+44.2%+85.2%11.0%—$362.9MCompare

News about X4 Pharmaceuticals

All news →
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM SyndromeGlobeNewswire Inc. · Feb 27, 2026▲ Positive

Quick answers

What does X4 Pharmaceuticals do?
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy.
What is XFOR's market cap?
$321.24M, based on the Nov 4 close of $3.24.
Does X4 Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of XFOR is sold short?
7.5M shares, 9.3% of float, as of Oct 15, 2026.
What sector is XFOR in?
Healthcare, in the Biotechnology industry.

About X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

HQ: Boston, MA45 employeesListed Nov 16, 2017x4pharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology